European Medicines Agency gives favourable ruling" on NSAIDs

Watson, Rory
October 2006
BMJ: British Medical Journal (International Edition);10/28/2006, Vol. 333 Issue 7574, p873
Academic Journal
The article focuses on a ruling by the London based European Medicines Agency which said that the benefits of the use of non-steroidal anti-inflammatory drugs (NSAIDs) outweigh the risks. The agency, after reviewing research, determined that the drugs provided important treatment for painful conditions such as arthritis, and were relatively safe, despite a small increase in thrombotic events such as heart attacks and strokes which was seen with their use.


Related Articles

  • FDA criticized on nonsteroidals. Kincade, Kathy // Ophthalmology Times;8/7/95, Vol. 20 Issue 30, p1 

    Reports on the meeting of the Food and Drug Administration's (FDA) Ophthalmic Devices Advisory Panel regarding the regulation of anti-inflammatory nonsteroidal drugs. FDA's regulation of postoperative regimens related to photorefractive keratectomy; Comments from Emma Knight, a clinician with...

  • Children's motrin goes OTC.  // FDA Consumer;Sep95, Vol. 29 Issue 7, p2 

    Reports that the Food and Drug Administration has approved a children's form of the nonsteroidal antiinflammatory drug Motrin or ibuprofen for over-the-counter (OTC) use. Therapeutic uses; Labeling.

  • Ibuprofen redux. Sibbald, Barbara // CMAJ: Canadian Medical Association Journal;10/10/2006, Vol. 175 Issue 8, p858 

    The article explains the stance of Health Canada on the safety of ibuprofen. The result of an internal scientific review of the safety of ibuprofen is discussed. A correlation between cardiovascular risk and high-dose of ibuprofen is presented. A statement from Doctor Marc Berthiaume, director...

  • Children's ibuprofen goes OTC.  // Pediatrics for Parents;1995, Vol. 16 Issue 4, p7 

    Reports that the Food and Drug Administration has approved the over-the-counter sale of ibuprofen. Labeling advise to parents.

  • FDA Issues Advice on COX-2 Inhibitors. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;2/2/2005, Vol. 97 Issue 3, p171 

    Reports on the issuance of a public health advisory on non-steroidal anti-inflammatory drugs by the U.S. Food and Drug Administration. Potential of the long-term use of the drugs to increase a person's risk of cardiovascular events; Evaluation of all ongoing prevention trials using celecoxib and...

  • TGA's review on OTC oral NSAIDs: labelling changes.  // Reactions Weekly;Nov2015, Vol. 1579 Issue 1, p6 

    The article reports that the Australian Therapeutic Goods Administration (TGA) has assessed submissions from organizations or sponsors on its review of over-the-counter (OTC) oral nonsteroidal anti-inflammatories (NSAID) and made consensus on labelling changes.

  • TGA seeks input for RASMLs for six NSAIDs.  // Reactions Weekly;Feb2015, Vol. 1539 Issue 1, p4 

    The article reports on the Australian Therapeutic Goods Administration's (TGA) proposed Required Advisory Statements for Medicine Labels (RASML) documents relating to oral non-prescription nonsteroidal anti-inflammatory drugs (NSAID) that include diclofenac, flurbiprofen and ibuprofen.

  • EMA recommends new measures for safer use of fibrin sealants.  // Reactions Weekly;11/24/2012, Issue 1429, p2 

    The article reports on the risk minimisation recommended by the European Medicines Agency (EMA) for the safer use of surgeons for fibrin sealants Evicel and Quixil.

  • Restrictions on hydroxyzine use to reduce cardiac risk.  // Reactions Weekly;May2015, Vol. 1551 Issue 1, p5 

    The article reports that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has reviewed the risk of the torsades de pointes and QT interval prolongation in patients who are receiving hydroxyzine-containing products.


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics